Amgen Inc Valuation – June 2018 $AMGN
Company Profile (excerpt from Reuters): Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Downloadable PDF version of this valuation:
ModernGraham Valuation of AMGN – June 2018
Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?
What kind of Intelligent Investor are you?
| Defensive Investor; must pass 6 out of the following 7 tests. | ||||
| 1. Adequate Size of the Enterprise | Market Cap > $2Bil | $122,514,875,748 | Pass | |
| 2. Sufficiently Strong Financial Condition | Current Ratio > 2 | 3.88 | Pass | |
| 3. Earnings Stability | Positive EPS for 10 years prior | Pass | ||
| 4. Dividend Record | Dividend Payments for 10 years prior | Fail | ||
| 5. Earnings Growth | Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end | 90.93% | Pass | |
| 6. Moderate PEmg Ratio | PEmg < 20 | 21.53 | Fail | |
| 7. Moderate Price to Assets | PB Ratio < 2.5 OR PB*PEmg < 50 | 8.43 | Fail | |
| Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor. | ||||
| 1. Sufficiently Strong Financial Condition | Current Ratio > 1.5 | 3.88 | Pass | |
| 2. Sufficiently Strong Financial Condition | Debt to NCA < 1.1 | 1.10 | Fail | |
| 3. Earnings Stability | Positive EPS for 5 years prior | Pass | ||
| 4. Dividend Record | Currently Pays Dividend | Pass | ||
| 5. Earnings Growth | EPSmg greater than 5 years ago | Pass | ||
Stage 2: Determination of Intrinsic Value
| EPSmg | $8.60 |
| MG Growth Estimate | 6.62% |
| MG Value | $187.01 |
| Opinion | Fairly Valued |
| MG Grade | B- |
| MG Value based on 3% Growth | $124.70 |
| MG Value based on 0% Growth | $73.10 |
| Market Implied Growth Rate | 6.51% |
| Current Price | $185.15 |
| % of Intrinsic Value | 99.01% |
Amgen, Inc. is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor is only concerned with the level of debt relative to the net current assets. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.
As for a valuation, the company appears to be Fairly Valued after growing its EPSmg (normalized earnings) from $5.97 in 2014 to an estimated $8.6 for 2018. This level of demonstrated earnings growth supports the market’s implied estimate of 6.51% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value within a margin of safety relative to the price.
At the time of valuation, further research into Amgen, Inc. revealed the company was trading above its Graham Number of $99.3. The company pays a dividend of $4.6 per share, for a yield of 2.5%, putting it among the best dividend paying stocks today. Its PEmg (price over earnings per share – ModernGraham) was 21.53, which was below the industry average of 37.68, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-20.89.
Amgen, Inc. performs fairly well in the ModernGraham grading system, scoring a B-.
Stage 3: Information for Further Research
| Net Current Asset Value (NCAV) | -$20.89 |
| Graham Number | $99.30 |
| PEmg | 21.53 |
| Current Ratio | 3.88 |
| PB Ratio | 8.43 |
| Current Dividend | $4.60 |
| Dividend Yield | 2.48% |
| Number of Consecutive Years of Dividend Growth | 7 |
Useful Links:
| ModernGraham tagged articles | Morningstar |
| Google Finance | MSN Money |
| Yahoo Finance | Seeking Alpha |
| GuruFocus | SEC Filings |
Most Recent Balance Sheet Figures
| Balance Sheet Information | 3/1/2018 |
| Total Current Assets | $40,689,000,000 |
| Total Current Liabilities | $10,479,000,000 |
| Long-Term Debt | $33,358,000,000 |
| Total Assets | $71,164,000,000 |
| Intangible Assets | $23,550,000,000 |
| Total Liabilities | $55,544,000,000 |
| Shares Outstanding (Diluted Average) | 711,000,000 |
Earnings Per Share History
| EPS History | |
| Next Fiscal Year Estimate | $12.54 |
| Dec2017 | $2.69 |
| Dec2016 | $10.24 |
| Dec2015 | $9.06 |
| Dec2014 | $6.70 |
| Dec2013 | $6.64 |
| Dec2012 | $5.52 |
| Dec2011 | $4.04 |
| Dec2010 | $4.79 |
| Dec2009 | $4.51 |
| Dec2008 | $3.77 |
| Dec2007 | $2.82 |
| Dec2006 | $2.48 |
| Dec2005 | $2.93 |
| Dec2004 | $1.81 |
| Dec2003 | $1.69 |
| Dec2002 | -$1.21 |
| Dec2001 | $1.03 |
| Dec2000 | $1.05 |
| Dec1999 | $1.02 |
| Dec1998 | $0.82 |
Earnings Per Share – ModernGraham History
| EPSmg History | |
| Next Fiscal Year Estimate | $8.60 |
| Dec2017 | $6.78 |
| Dec2016 | $8.42 |
| Dec2015 | $7.14 |
| Dec2014 | $5.97 |
| Dec2013 | $5.43 |
| Dec2012 | $4.73 |
| Dec2011 | $4.22 |
| Dec2010 | $4.09 |
| Dec2009 | $3.60 |
| Dec2008 | $3.02 |
| Dec2007 | $2.54 |
| Dec2006 | $2.11 |
| Dec2005 | $1.70 |
| Dec2004 | $1.02 |
| Dec2003 | $0.65 |
| Dec2002 | $0.27 |
Recommended Reading:
Other ModernGraham posts about the company
Other ModernGraham posts about related companies
Disclaimer:
The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.
